The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy AMX0035 in people with Alzheimer’s disease. Top-line results from the trial are expected in the first half of 2021. “The PEGASUS trial design and broad inclusion criteria will allow us to assess whether AMX0035 can prevent neurodegeneration in people with Alzheimer’s via MR imaging and fluid…
You must be logged in to read/download the full post.
The post Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year appeared first on BioNewsFeeds.